Innovation-driven + Global layout shows results, BIOCYTOGEN-B's revenue increased by 50% in the first half of the year, achieving sustained profitability

According to the Zhitong Finance APP, on August 4th, BIOCYTOGEN-B (02315) announced its performance forecast for the first half of 2025. According to the disclosure, BIOCYTOGEN expects its revenue for the first half of the year to reach RMB 616 million to RMB 626 million, a year-on-year increase of approximately 50.1% to 52.5%; R&D expenses are expected to be RMB 206.1 million to RMB 216.1 million, a year-on-year increase of approximately 27.5% to 33.6%; the company expects to achieve a net profit of RMB 42.7 million to RMB 52.7 million, turning losses into profits year-on-year. Overall, BIOCYTOGEN achieved significant revenue growth, continuous R&D investment, and sustained profitability in the first half of 2025 through a multi-faceted approach, including adhering to an innovation-driven strategy, strengthening domestic and international market expansion, and optimizing its internal management system. This achievement is attributed to BIOCYTOGEN's multi-faceted strategic layout and effective execution. The company has maintained a high level of R&D intensity and continuously adjusted the total R&D investment and key R&D directions dynamically based on business development and strategic needs. In terms of market expansion, the company has continuously strengthened its overseas market layout in the first half of the year, promoting rapid growth in overseas business by expanding its sales team and improving its sales system. At the same time, the release of R&D demand from domestic biopharmaceutical companies has also brought development opportunities for BIOCYTOGEN. The preclinical product and service business segment, centered on innovative animal models and preclinical CRO services, as well as the antibody molecule transfer and development business segment, achieved rapid revenue growth in both domestic and overseas markets in the first half of the year while maintaining a high gross profit margin. In the secondary market, with the recent continuous recovery of the Hong Kong stock biopharmaceutical sector, BIOCYTOGEN's stock price has surged. As of July 28th, BIOCYTOGEN's stock price has soared from a low of HKD 5.6 at the end of November last year to HKD 21.45, an increase of nearly 300%, with a year-to-date increase exceeding 150%, far outperforming the Hang Seng Index and the Hang Seng Tech Index. Platform Value Deepening, Driving Core Business Growth BIOCYTOGEN has built a strong core technology barrier with its unique gene editing technology and animal model platform. It has laid out thousands of high-value target models around more than 20 key disease areas, including tumors, autoimmune diseases, metabolic diseases, and neurological disorders, widely applied in drug target validation, functional mechanism research, preclinical research, and safety evaluation. It continues to attract and serve nearly 900 pharmaceutical companies and research institutions worldwide, completing over 5,300 drug evaluation projects, providing a solid revenue foundation and significant scale effect for the company's preclinical products and services business. Diversified Monetization Models Strengthen Profitability In terms of antibody licensing and development business, the company has built a resource library of over one million fully human antibody molecules based on the RenMice® platform, capable of large-scale output of differentiated antibody molecules. By the end of 2024, BIOCYTOGEN has reached approximately 200 cooperation agreements with multiple domestic and foreign pharmaceutical companies, with over 50 licensed projects from the RenMice® platform covering multiple innovative targets, continuously bringing licensing revenue and potential milestone returns to the company, effectively supporting the sustained improvement of the company's overall profitability and maintaining a high gross profit margin level Overall, BIOCYTOGEN is rapidly expanding its revenue sources by continuously enhancing platform construction and accelerating the commercialization of project results. As overseas collaborations deepen and the scale of preclinical services expands, coupled with the release of growth momentum in antibody licensing business, the company's value in the innovative drug industry chain is expected to continue to increase in the future